Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$4.63 - $9.94 $6.39 Million - $13.7 Million
-1,379,846 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$8.35 - $12.6 $2.55 Million - $3.85 Million
305,321 Added 28.41%
1,379,846 $12.6 Million
Q3 2021

Nov 09, 2021

SELL
$10.13 - $15.0 $397,784 - $589,020
-39,268 Reduced 3.53%
1,074,525 $11.5 Million
Q2 2021

Aug 16, 2021

BUY
$13.27 - $18.48 $1.01 Million - $1.4 Million
75,998 Added 7.32%
1,113,793 $17.3 Million
Q1 2021

May 14, 2021

SELL
$14.49 - $20.72 $4.56 Million - $6.53 Million
-314,959 Reduced 23.28%
1,037,795 $16.8 Million
Q4 2020

Feb 08, 2021

SELL
$14.61 - $22.14 $3.77 Million - $5.71 Million
-257,845 Reduced 16.01%
1,352,754 $28.6 Million
Q3 2020

Nov 09, 2020

BUY
$13.67 - $17.77 $15.1 Million - $19.6 Million
1,102,196 Added 216.8%
1,610,599 $23.9 Million
Q2 2020

Aug 10, 2020

BUY
$10.89 - $21.47 $69,870 - $137,751
6,416 Added 1.28%
508,403 $7.48 Million
Q1 2020

May 14, 2020

BUY
$10.23 - $24.56 $4.73 Million - $11.4 Million
462,236 Added 1162.83%
501,987 $5.89 Million
Q4 2019

Feb 12, 2020

SELL
$17.42 - $26.61 $32,070 - $48,989
-1,841 Reduced 4.43%
39,751 $934,000
Q3 2019

Nov 08, 2019

BUY
$16.36 - $21.39 $62,249 - $81,388
3,805 Added 10.07%
41,592 $769,000
Q2 2019

Jul 25, 2019

BUY
$16.93 - $26.22 $156,890 - $242,980
9,267 Added 32.49%
37,787 $702,000
Q1 2019

May 08, 2019

SELL
$23.15 - $28.34 $569,536 - $697,220
-24,602 Reduced 46.31%
28,520 $697,000
Q4 2018

Feb 05, 2019

SELL
$22.03 - $32.01 $8,481 - $12,323
-385 Reduced 0.72%
53,122 $1.38 Million
Q3 2018

Nov 13, 2018

BUY
$30.0 - $40.85 $1.61 Million - $2.19 Million
53,507 New
53,507 $1.69 Million

Others Institutions Holding HRTX

About HERON THERAPEUTICS, INC.


  • Ticker HRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,774,000
  • Market Cap $210M
  • Description
  • Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...
More about HRTX
Track This Portfolio

Track Rothschild & CO Asset Management Us Inc. Portfolio

Follow Rothschild & CO Asset Management Us Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rothschild & CO Asset Management Us Inc., based on Form 13F filings with the SEC.

News

Stay updated on Rothschild & CO Asset Management Us Inc. with notifications on news.